Maze Therapeutics, Inc. (MAZE) Price & Analysis

Compare

27 Followers

MAZE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.71 - $19.19

Previous CloseN/A

VolumeN/A

Average Volume (3M)148.06K

Market Cap

$585.41M

Enterprise Value$298.52M

Total Cash (Recent Filing)$264.54M

Total Debt (Recent Filing)$25.01M

Price to Earnings (P/E)―

Beta0.83

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding43,850,883

10 Day Avg. Volume169,167

30 Day Avg. Volume148,056

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.51

Enterprise Value/Revenue119.41

Enterprise Value/Gross Profit646.14

Enterprise Value/Ebitda-2.40

Forecast

1Y Price Target

$26.75

Price Target Upside100.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment continues to progress in the Ph.2 HORIZON study for lead asset MZE829, an inhibitor of apolipoprotein L1 (APOL1).

Financial PositionThe company ended the quarter with $264.5M in cash and cash equivalents, which is expected to provide runway into the second half of 2027.

InnovationMaze’s proprietary COMPASS platform uniquely transforms human genetic variant information into mechanism-based drug programs, positioning the company as a leader in precision nephrology.

Bears Say

Regulatory ChallengesMaze plans to initiate two parallel Ph.2 clinical trials in chronic kidney disease (CKD) and phenylketonuria (PKU) in 2026 based on the Ph.1 results.

ValuationThe stock is considered undervalued at the current valuation, given the strong human genetics evidence supporting the SLC6A19 approach.

Maze Therapeutics, Inc. News

Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)

“With two clinical-stage programs advancing, Maze continues to execute with focus and discipline,” said Jason Coloma, chief executive...

5d ago

MAZE

Maze Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $34 price target The company’s...

25d ago

MAZE

Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health

Analyst Joseph Schwartz of Leerink Partners maintained a Buy rating on Maze Therapeutics, Inc., retaining the price target...

2d ago

MAZE

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on MAZE stock, giving a Buy rating...

4d ago

MAZE

Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782

H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on Maze Therapeutics, Inc. today and set a price...

4d ago

MAZE

Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock

Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by H.C. Wainwright analyst, Ananda Ghosh. Ananda...

25d ago

MAZE

Maze Therapeutics participates in a conference call with JPMorgan

JPMorgan addresses top 10 questions with management on a conference call to be held on July 14 at...

1M ago

MAZE

Wedbush bullish on Maze Therapeutics, initiates with an Outperform

As previously reported, Wedbush analyst Laura Chico initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and...

1M ago

MAZE

Maze Therapeutics initiated with an Outperform at Wedbush

Wedbush initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $17 price target Published first on...

1M ago

MAZE

Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position

Maze Therapeutics, Inc. (MAZE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

3M ago

MAZE

Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on MAZE stock, giving a Buy rating yesterday....

5M ago

MAZE

Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year

“Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with...

5M ago

MAZE

Block upgraded, Domino’s downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

6M ago

Maze Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $28 price target Maze is a...

6M ago

MAZE

MAZE FAQ

What was Maze Therapeutics, Inc.’s price range in the past 12 months?

Maze Therapeutics, Inc. lowest stock price was $6.71 and its highest was $19.19 in the past 12 months.

What is Maze Therapeutics, Inc.’s market cap?

Maze Therapeutics, Inc.’s market cap is $585.41M.

When is Maze Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Maze Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Maze Therapeutics, Inc. overvalued?

According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Maze Therapeutics, Inc. pay dividends?

Maze Therapeutics, Inc. does not currently pay dividends.

What is Maze Therapeutics, Inc.’s EPS estimate?

Maze Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Maze Therapeutics, Inc. have?

Maze Therapeutics, Inc. has 43,850,883 shares outstanding.

What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?

Currently, no hedge funds are holding shares in MAZE

Maze Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

236.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE) is a biotechnology company focused on translating genetic insights into novel therapeutic approaches for treating a range of diseases. Operating within the biotechnology and pharmaceutical sectors, Maze leverages its proprietary COMPASS platform to identify and validate genetic modifiers, which are then developed into potential therapeutic products. The company's core focus is on discovering genetic pathways that can be modulated to treat diseases with significant unmet medical needs.

Maze Therapeutics, Inc. (MAZE) Earnings & Revenues

Historic Earnings Reports

MAZE Stock 12 Month Forecast

Average Price Target

$26.75

▲(100.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","35":"$35","14.75":"$14.75","21.5":"$21.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.75,21.5,28.25,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,16.369230769230768,17.838461538461537,19.307692307692307,20.776923076923076,22.246153846153845,23.715384615384615,25.184615384615384,26.653846153846153,28.123076923076923,29.592307692307692,31.06153846153846,32.53076923076923,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.811538461538461,16.723076923076924,17.634615384615387,18.546153846153846,19.45769230769231,20.369230769230768,21.28076923076923,22.192307692307693,23.103846153846156,24.015384615384615,24.926923076923075,25.838461538461537,{"y":26.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.061538461538461,15.223076923076924,15.384615384615385,15.546153846153846,15.707692307692309,15.86923076923077,16.03076923076923,16.192307692307693,16.353846153846153,16.515384615384615,16.676923076923078,16.838461538461537,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >